NCT03329014View on ClinicalTrials.gov

A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

June 9, 2017

Study Completion Date

June 14, 2017

Conditions

Procedural Sedation

Interventions

DRUG

Remimazolam

For induction and maintenance of sedation

DRUG

Placebo

Control arm

Trial Locations (1)

84106

PRA Health Sciences, Salt Lake City

Sponsors

Collaborators (1)

PRA Health Sciences

All Listed Sponsors

collaborator

PRA Health Sciences

INDUSTRY

lead

Paion UK Ltd.

INDUSTRY